Coagulation factors are protein components of the blood which serve blood coagulation.
Search results 1 to 25 from a total of 90
| Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|
WILLFACT 2000 I.E. |
LFB-Biomedicaments |
PEI.H.03530.03.1 | 24.12.2014 | |
WILLFACT 1000 I.E. |
LFB-Biomedicaments |
PEI.H.03530.01.1 | 15.05.2009 | |
WILLFACT 500 I.E. |
LFB-Biomedicaments |
PEI.H.03530.02.1 | 24.12.2014 | |
Wilate 1000 |
EurimPharm Arzneimittel GmbH |
PEI.H.12128.01.1 | 27.10.2021 | |
|
Wilate 1000 |
OCTAPHARMA GmbH |
PEI.H.01918.04.1 | 22.12.2011 | |
|
Wilate 900 |
OCTAPHARMA GmbH |
PEI.H.01918.02.1 | 08.02.2005 | |
|
Wilate 500 |
OCTAPHARMA GmbH |
PEI.H.01918.03.1 | 22.12.2011 | |
|
Wilate 450 |
OCTAPHARMA GmbH |
PEI.H.01918.01.1 | 08.02.2005 | |
|
Voncento |
CSL Behring GmbH |
EU/1/13/857 | 12.08.2013 | |
|
Vihuma |
Octapharma AB, Stockholm |
EU/1/16/1168 | 13.02.2017 | |
|
Veyvondi |
Baxalta Innovations GmbH |
EU/1/18/1298 | 31.08.2018 | |
|
Rixubis |
Baxter Innovations GmbH |
EU/1/14/970 | 19.12.2014 | |
|
Riastap 1 g |
CSL Behring GmbH |
PEI.H.04771.01.1 | 03.12.2009 | Rote-Hand-Brief: Haemocomplettan und Riastap (01.04.2019) |
|
Refixia |
Novo Nordisk A/S, Denmark |
EU/1/17/1193 | 02.06.2017 | |
ReFacto AF |
Pfizer Europe MA EEIG |
EU/1/99/103 | 13.04.1999 | |
Recombinate Antihaemophilie Faktor (rekombinant) 1000 |
Takeda GmbH |
28530.02.00 | 30.07.1993 | |
Prothromplex NF 600 |
Takeda GmbH |
PEI.H.11717.01.1 | 13.08.2014 | |
Prothromplex NF 500 |
Takeda GmbH |
PEI.H.11717.02.1 | 21.04.2023 | |
|
Octaplex 1000 |
OCTAPHARMA GmbH |
PEI.H.02312.02.1 | 11.08.2015 | |
|
OCTAPLEX 500 |
OCTAPHARMA GmbH |
PEI.H.02312.01.1 | 14.03.2003 | |
|
OCTANINE F 1000 |
OCTAPHARMA GmbH |
10501a/97-3 | 07.09.2000 | |
|
OCTANINE F 500 |
OCTAPHARMA GmbH |
10501a/97-2 | 07.09.2000 | |
Octanate 1000 |
CC-Pharma GmbH |
PEI.H.12112.01.1 | 05.07.2021 | |
|
Octanate 1000 |
OCTAPHARMA GmbH |
10500a/97-3 | 04.08.1998 | |
Octanate 1000 |
Orifarm GmbH |
PEI.H.12088.01.1 | 24.03.2021 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 520 in BAnz AT 22.08.2024 B6.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 22.08.2024
